FLAMINGO-01 AND GLSI-100

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Retrieved on: 
Thursday, March 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Breast, Trastuzumab, Recurrence, Patient, Immunotherapy, Research, Phase, Greenwich, Woman, Population, Forward-looking statement, Strathcona County, Twitter, Breast cancer, MD Anderson Cancer Center, HLA, AACR, HER2/neu, Company, DTH, SEC, Cancer, Patent, Medicine, 2021 Essex County Council election, Nasdaq, Survivor, Prospectus, Pharmaceutical industry, GP2, the AACR Annual Meeting 2022, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, THE AACR ANNUAL MEETING 2022, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Three abstracts/posters were accepted for presentation at the upcoming AACR Annual Meeting 2022.

Key Points: 
  • Three abstracts/posters were accepted for presentation at the upcoming AACR Annual Meeting 2022.
  • If these patent claims are issued, they have the potential to extend the patent life of GP2 beyond 2040.
  • The Phase III clinical trial will be called FLAMINGO-01 and the combination of GP2 + GM-CSF will be called GLSI-100.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Retrieved on: 
Thursday, February 3, 2022
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, CEO, Forward-looking statement, Patient, MD Anderson Cancer Center, Cancer, SEC, Twitter, Immunotherapy, Woman, GM-CSF, Survivor, Population, Prospectus, Recurrence, Company, Breast, DTH, HER2/neu, Phase, Trastuzumab, Investment, BIO, HLA, Breast cancer, Conference, Greenwich, Nasdaq, Pharmaceutical industry, GP2, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will present in-person at 2:30 pm ET on February 14, 2022 at the 2022 BIO CEO & Investor Conference and will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will present in-person at 2:30 pm ET on February 14, 2022 at the 2022 BIO CEO & Investor Conference and will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • The 2022 BIO CEO & Investor Conference will be held from February 14-17, 2022.
  • For more than 20 years, the BIO CEO & Investor Conference has fueled biotech industry networking with premier investor and banking communities, focused on established and emerging publicly traded and select private biotech companies.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Retrieved on: 
Tuesday, February 1, 2022
Oncology, Health, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, Forward-looking statement, Patient, MD Anderson Cancer Center, Cancer, SEC, Data management, Twitter, Immunotherapy, Woman, Survivor, Population, Prospectus, Recurrence, Contract research organization, Company, Breast, DTH, HER2/neu, Phase, Trastuzumab, CRO, HLA, Breast cancer, Greenwich, Nasdaq, Pharmaceutical industry, GP2, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides an update on the Phase III clinical trial, FLAMINGO-01.

Key Points: 
  • Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides an update on the Phase III clinical trial, FLAMINGO-01.
  • This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Retrieved on: 
Monday, January 24, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Greenwich, Trastuzumab, Forward-looking statement, HER2/neu, Patient, SEC, IPO, Board of directors, Population, MD Anderson Cancer Center, Breast cancer, Breast, HLA, Survivor, Cancer, Recurrence, Time, Nasdaq, GM-CSF, Company, DTH, Phase, Twitter, Immunotherapy, Prospectus, Share repurchase, Director, Board, Woman, Pharmaceutical industry, GP2, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

The term of the board authorization of the repurchase program is until March 31, 2023.

Key Points: 
  • The term of the board authorization of the repurchase program is until March 31, 2023.
  • The repurchase program may be suspended or discontinued at any time and will be funded using the company's working capital.
  • CEO Snehal Patel commented, The implementation of this board-approved share repurchase program provides us with another tool to deliver shareholder value.
  • The Phase III clinical trial will be called FLAMINGO-01 and the combination of GP2 + GM-CSF will be called GLSI-100.

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Retrieved on: 
Wednesday, December 15, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Survivor, Forward-looking statement, Phase, TD Ameritrade, Breast, HLA, Company, GM-CSF, Interpol Terrorism Watch List, Cancer, Diagnosis, Population, Nasdaq, Woman, Breast cancer, SEC, TD Ameritrade Network, Immunotherapy, Trastuzumab, Patient, DNA, MD Anderson Cancer Center, Interview, Recurrence, DTH, HER2/neu, Twitter, Watchlist, Greenwich, TD, Prospectus, Pharmaceutical industry, Vaccine, GP2, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Mr. Patel appeared for a second time as a featured guest in a live interview on TD Ameritrade Network's The Watch List with host Nicole Petallides.

Key Points: 
  • Mr. Patel appeared for a second time as a featured guest in a live interview on TD Ameritrade Network's The Watch List with host Nicole Petallides.
  • However, an immune response was seen in these patients before any treatment with GP2, suggesting that their cancer was already recurring.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Retrieved on: 
Thursday, December 9, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Twitter, Trastuzumab, Risk, Population, SEC, Technology, Publication, Woman, Survivor, Breast cancer, Kaplan–Meier estimator, Recurrence, PIS, IIB, HER2/neu, Nasdaq, Poster, Andrew Mittendorf, HLA, Forward-looking statement, MD Anderson Cancer Center, Cancer, American Association for Cancer Research, Patient, University of Texas Health Science Center at San Antonio, Nominal interest rate, Multimedia, American Association, Breast, Table, Company, Prospectus, Immunotherapy, GM-CSF, Phase, Baylor College of Medicine, Skin test, DNA, HER2, Neoplasm, IHC, Șaeș, Safety, DFS, Time, DTH, Greenwich, Association, GM, Pharmaceutical industry, Health insurance, Vaccine, SABCS, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, SABCS, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Expansion into GP2 specific CAR-T cells could potentially become another platform technology to complement GP2 peptide treatment in higher risk patients.

Key Points: 
  • Expansion into GP2 specific CAR-T cells could potentially become another platform technology to complement GP2 peptide treatment in higher risk patients.
  • We expect new T cell data from the Phase III trial to become available in 2022.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on GP2 immune response and clinical data, please visit the Companys clinical trial tab at https://greenwichlifesciences.com/clinical-trials/ .

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Retrieved on: 
Wednesday, December 8, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Twitter, Company, TD Ameritrade Network, Trastuzumab, Forward-looking statement, Population, Prospectus, SEC, Immunotherapy, Conference, Publication, MD Anderson Cancer Center, Woman, Survivor, Phase, Clinical, Cancer, Russell 2000 Index, Patient, Breast cancer, TD, CEO, Russell, Recurrence, Data monitoring committee, BIO, Interpol Terrorism Watch List, DTH, Bloomberg Television, Greenwich, Breast, HER2, HER2/neu, Interview, Nasdaq, Watchlist, Poster, Biotechnology, HLA, Pharmaceutical industry, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that the Company will participate in the following interviews and conferences.

Key Points: 
  • Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that the Company will participate in the following interviews and conferences.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .
  • Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Retrieved on: 
Tuesday, December 7, 2021
Pharmaceutical, Health, Oncology, Clinical Trials, Twitter, Trastuzumab, Company, Forward-looking statement, Population, Prospectus, SEC, Immunotherapy, Biotechnology, GM-CSF, MD Anderson Cancer Center, Woman, Safety, Survivor, Phase, Cancer, Bachelor of Engineering, Patient, Breast cancer, Monitoring, Recurrence, MD, MS, DTH, University, Greenwich, Carnegie Mellon University, Breast, Washington University in St. Louis, HER2, HER2/neu, Hematological Cancer Research Investment and Education Act, Nasdaq, University of Nebraska Medical Center, HLA, Pharmaceutical industry, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Dr. Daugherty commented, I look forward to supporting the GLSI-100 clinical trials as Medical Monitor.

Key Points: 
  • Dr. Daugherty commented, I look forward to supporting the GLSI-100 clinical trials as Medical Monitor.
  • While GP2 has been shown to be both effective and safe in the Phase IIb trial, we will maintain our vigilance in the larger Phase III trial.
  • The Phase III clinical trial will be called FLAMINGO-01 and the combination of GP2 + GM-CSF will be called GLSI-100.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Retrieved on: 
Monday, December 6, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Patient, HLA, Trastuzumab, Cancer, MD Anderson Cancer Center, Industry, Time, Forward-looking statement, Company, Population, Woman, Recurrence, SEC, BLA, Breast, Breast cancer, Prospectus, Nasdaq, Twitter, Risk, Phase, CRO, DTH, Biologics license application, Greenwich, GM, Immunotherapy, Survivor, HER2/neu, Pharmaceutical industry, Fine chemical, Vaccine, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

Three commercial lots of GP2 will be required to file a Biologics License Application (BLA) for GP2.

Key Points: 
  • Three commercial lots of GP2 will be required to file a Biologics License Application (BLA) for GP2.
  • GP2 active ingredient manufacturer has been engaged to produce commercial scale GP2 lots.
  • Commercial testing laboratory has been engaged to release clinical and commercial GP2 lots and to manage GP2 stability program.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Retrieved on: 
Thursday, November 18, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Interview, HER2, HLA, Trastuzumab, Cancer, MD Anderson Cancer Center, Publication, Forward-looking statement, Company, Population, Woman, Recurrence, SEC, Breast, Wall Street, Breast cancer, Prospectus, Nasdaq, Twitter, Phase, DTH, Bloomberg Television, Greenwich, Russell, Immunotherapy, Survivor, HER2/neu, Russell 2000 Index, Pharmaceutical industry, The RedChip Money Report, FLAMINGO-01 and GLSI-100, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc., GP2 Immunotherapy Immune Response, THE REDCHIP MONEY REPORT, FLAMINGO-01 AND GLSI-100, BREAST CANCER AND HER2/NEU POSITIVITY, GREENWICH LIFESCIENCES, INC., GP2 IMMUNOTHERAPY IMMUNE RESPONSE

The RedChip Money Report delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, and financial book reviews, as well as featured interviews with executives of public companies.

Key Points: 
  • The RedChip Money Report delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, and financial book reviews, as well as featured interviews with executives of public companies.
  • The Phase III clinical trial will be called FLAMINGO-01 and the combination of GP2 + GM-CSF will be called GLSI-100.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .